In other words, increased m6A methylation and high FUS expression upregulate P53 and GPX4 levels, and downregulate the NRF2/HO-1 pathway to inhibit ferroptosis and accelerate PRAD. The gene discussed is FUS; the disease is prostate adenocarcinoma.